Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 51,921 Shares

Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu sold 51,921 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Xiaobin Wu also recently made the following trade(s):

• On Wednesday, March 5th, Xiaobin Wu sold 51,921 shares of Beigene stock. The shares were sold at an average price of $261.59, for a total transaction of $13,582,014.39.
• On Thursday, February 20th, Xiaobin Wu sold 21,267 shares of Beigene stock. The stock was sold at an average price of $240.07, for a total value of $5,105,568.69.
• On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The stock was sold at an average price of $240.74, for a total value of $7,379,643.96.

Beigene Stock Down 3.8 %

Shares of Beigene stock traded down $10.46 on Thursday, reaching $264.32. The company’s stock had a trading volume of 389,916 shares, compared to its average volume of 460,234. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. The stock has a market capitalization of $26.07 billion, a PE ratio of -32.08, a price-to-earnings-growth ratio of 7.73 and a beta of 0.65. Beigene, Ltd. has a 52-week low of $126.97 and a 52-week high of $287.88.

Beigene (NASDAQ:ONC) last released its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.55). Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The firm had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. On average, analysts anticipate that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ONC. Sanford C. Bernstein set a $259.00 price objective on shares of Beigene in a report on Thursday, March 13th. Guggenheim reissued a “buy” rating on shares of Beigene in a research report on Friday, February 28th. Macquarie upped their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th. JMP Securities set a $348.00 target price on shares of Beigene in a report on Friday, February 28th. Finally, Bank of America raised shares of Beigene from a “neutral” rating to a “buy” rating and upped their price target for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.